Eric Furfine
Co-Chief Executive & Scientific Officer Mosaic Bio
Seminars
Wednesday 28th January 2026
Technology for long-acting ocular therapeutics for posterior eye disease
12:30 pm
- Achieving durable efficacy in posterior segment eye diseases remains constrained by rapid intraocular clearance and frequent dosing requirements. While increasing molecular size is a proven strategy to extend vitreal half-life, common approaches such as PEGylation introduce trade-offs in biological activity, safety, and tissue penetration.
- In this presentation, we describe a protein engineering strategy developed at Mosaic Biosciences to extend intraocular pharmacokinetics using genetically encoded, large–hydrodynamic radius polypeptides composed of natural amino acids. This data highlights a modular, genetically encoded alternative to traditional size-expansion strategies and support its application to long-acting protein therapeutics for retinal diseases.
